Serum Erythropoietin in Heart Failure Patients Treated with ACE-Inhibitors or AT1 Antagonists

Abstract

We suggest that a desirable Epo increase in class III and IV CHF patients could be achieved by either recombinant human Epo administration or, possibly, by appropriate selection of the concomitant medical therapy. A large prospective study shall investigate the possible advantage of AT(1) antagonists over ACE-inhibitors with regard to Epo effect.